Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms TRA-CER
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 07 Nov 2022 Results assessing short- and long-term effects of vorapaxar (V) as compared to Placebo (PL) on the following biomarkers: Angiopoietin-2 (ANGPT2), Angiopoietin-like 4 (ANGPTL4), VEGF, ICAM-1, VCAM-1, E-Selectin (ESEL), von Willebrand Factor (VWF), Thrombomodulin (TM), PAI-1 and PAI-2 from TRA2P-TIMI 50 and TRACER presented at the American Heart Association Scientific Sessions 2022
- 01 Nov 2022 Results assessing Biomarker-Based Prediction( from two trials NCT00391872 and NCT00527943) of Recurrent Ischemic Events in Patients With Acute Coronary Syndromespublished in the Journal of the American College of Cardiology
- 11 Jul 2022 Results assessing cardiovascular outcomes in patients with DM presenting with ACS, stratified by PAD status from 4 randomized post-ACS trials (PLATO, APPRAISE-2, TRILOGY, and TRACE) published in the American Journal of Cardiology.